1

2
SMITH David Bernard, DEVAL Jerome, DYATKINA Natalia, BEIGELMAN Leonid, WANG Guangyi: ANALOGUES NUCLÉOTIDIQUES SUBSTITUÉS, SUBSTITUTED NUCLEOTIDE ANALOGS. ALIOS BIOPHARMA, SMITH David Bernard, DEVAL Jerome, DYATKINA Natalia, BEIGELMAN Leonid, WANG Guangyi, MILLER Kimberly J, March 29, 2012: WO/2012/040127 (14 worldwide citation)

Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.


3
BEIGELMAN Leonid, BLATT Lawrence, WANG Guangyi, RAJWANSHI Vivek Kumar, DYATKINA Natalia, SMITH David Bernard: ANALOGUES DE NUCLÉOTIDES SUBSTITUÉS, SUBSTITUTED NUCLEOTIDE ANALOGS. ALIOS BIOPHARMA, BEIGELMAN Leonid, BLATT Lawrence, WANG Guangyi, RAJWANSHI Vivek Kumar, DYATKINA Natalia, SMITH David Bernard, MILLER Kimberly J, March 29, 2012: WO/2012/040126 (11 worldwide citation)

Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.


4
Buckman Brad O, Wang Guangyi, Beigelman Leonid, Stoycheva Antitsa Dimitrova: Novel inhibitors of hepatitis c virus replication. Intermune, Buckman Brad O, Wang Guangyi, Beigelman Leonid, Stoycheva Antitsa Dimitrova, MALLON Joseph J, November 5, 2009: WO/2009/134616 (10 worldwide citation)

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibr ...


5
BEIGELMAN Leonid, WANG Guangyi, SMITH David Bernard, DEVAL Jerome, PRHAVC Marija: [fr] NUCLÉOSIDES SUBSTITUÉS, NUCLÉOTIDES SUBSTITUÉS ET ANALOGUES DE CEUX-CI, [en] SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF. ALIOS BIOPHARMA, MILLER Kimberly J, June 27, 2013: WO/2013/096679 (8 worldwide citation)

[en] Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a con ...


6
BEIGELMAN Leonid, DEVAL Jerome, SMITH David Bernard, WANG Guangyi, RAJWANSHI Vivek Kumar: AZIDO NUCLÉOSIDES ET ANALOGUES NUCLÉOTIDIQUES, AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS. ALIOS BIOPHARMA, BEIGELMAN Leonid, DEVAL Jerome, SMITH David Bernard, WANG Guangyi, RAJWANSHI Vivek Kumar, MILLER Kimberly J, March 29, 2012: WO/2012/040124 (5 worldwide citation)

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a conditio ...


7
WANG Guangyi, BEIGELMAN Leonid: [fr] ANALOGUES DE NUCLÉOTIDE PHOSPHOROTHIOATE SUBSTITUÉS, [en] SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS. ALIOS BIOPHARMA, MILLER Kimberly J, June 27, 2013: WO/2013/096680 (4 worldwide citation)

[en] Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.


8
Wang Guangyi: Metabolically engineered organisms for the production of hydrogen and hydrogenase. University Of Hawaii, Wang Guangyi, ALTMAN Daniel E, August 9, 2007: WO/2007/089901 (3 worldwide citation)

The present application relates to the use of metabolically-engineered microbial cells for the production of hydrogen and hydrogenase enzymes. The microbial cells are strains of E. coli which are genetically engineered to optimize the cell for production of hydrogen or active hydrogenase. The strain ...


9
Wang Guangyi, Tam Robert, Avertt Deveron: Purine l-nucleosides, analogs and uses therof. Icn Pharmaceuticals, January 31, 2001: EP1072607-A2 (1 worldwide citation)

Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to tre ...


10
Wang Guangyi, Ramasamy Kandasamy, Seifert Wilfried: Sugar modified nucleosides and their use for synthesis of oligonucleotides. Icn Pharmaceuticals, Wang Guangyi, Ramasamy Kandasamy, Seifert Wilfried, FISH Robert D, May 17, 1996: WO/1996/014329 (1 worldwide citation)

A number of modified nucleosides are disclosed composed of modified sugar moieties which contain substituents at C1 and C4 positions, or branched substituents at C3 and C5 positions of deoxyribose or ribose. Each nucleoside is converted to or properly protected and them converted to the correspondin ...